Alpha-synuclein: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
← Older edit
Michal Harel (talk | contribs)
31,761 edits
No edit summary
Michal Harel (talk | contribs)
31,761 edits
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
<StructureSection load='6flt' size='340' side='right' caption='Human alpha-synuclein (PDB [[6flt]])' scene='84/840509/Cv/1'>
<StructureSection load='6h6b' size='340' side='right' caption='Human alpha-synuclein (PDB [[6h6b]])' scene='84/840509/Cv/1'>


== Function ==
== Function ==
Line 17: Line 17:
The Syn structure shows <scene name='84/840509/Cv/2'>8 β-sheet</scene> forming segments interrupted by <scene name='84/840509/Cv/4'>Gly residues</scene>. Seven PD-associated familial <scene name='84/840509/Cv/5'>mutations</scene> are known. The 3D structure shows a <scene name='84/840509/Cv/6'>hydrophobic cleft</scene> which can provide an entry point for an incoming Syn molecule elongating the fibril<ref>PMID:29969391</ref>.
The Syn structure shows <scene name='84/840509/Cv/2'>8 β-sheet</scene> forming segments interrupted by <scene name='84/840509/Cv/4'>Gly residues</scene>. Seven PD-associated familial <scene name='84/840509/Cv/5'>mutations</scene> are known. The 3D structure shows a <scene name='84/840509/Cv/6'>hydrophobic cleft</scene> which can provide an entry point for an incoming Syn molecule elongating the fibril<ref>PMID:29969391</ref>.


</StructureSection>
== 3D Structures of alpha-synuclein==
== 3D Structures of alpha-synuclein==
 
[[Alpha-synuclein 3D structures]]
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
 
[[6flt]], [[6h6b]], [[6a6b]], [[6cu7]], [[6cu8]], [[6l1t]], [[6l1u]], [[6l4s]], [[6lrq]],[[6rt0]], [[6rtb]], [[6sst]], [[6ssx]], [[6xyo]], [[6xyp]], [[6xyq]], [[6osj]], [[6osl]], [[6osm]], [[7c1d]], [[7l7h]], [[7nca]], [[7ncg]], [[7nch]], [[7nci]], [[7ncj]], [[7nck]], [[7ozg]], [[7ozh]], [[7v47]], [[7v48]], [[7v4a]], [[7v4b]], [[7v4c]], [[7v4d]], [[8a4l]] – hSyn – human - Cryo EM<br />
[[2n0a]] – hSyn – NMR<br />
[[6ufr]], [[6peo]], [[6pes]], [[7e0f]] – hSyn (mutant) - Cryo EM<br />
[[7lc9]] – hSyn 41-140 - Cryo EM<br />
[[8a9l]] – hSyn + peptide - Cryo EM<br />
[[7stx]] – hSyn + acetyltransferase + CoA - Cryo EM<br />
[[2m55]] – hSyn residues 1-19 + calmodulin – NMR<br />
[[6i42]] – hSyn residues 48-60 + cyclophilin A<br />
[[5crw]] – hSyn residues 31-41 + protein disulfide isomerase<br />
[[6ct7]] – hSyn residues 1-10 + antibody<br />
[[2x6m]] – hSyn residues 132-140 + antibody<br />
[[3q25]], [[3q26]], [[3q27]], [[3q28]], [[3q29]] – hSyn peptide/MBP<br />
[[3q26]] – hSyn residues 10-42/MBP<br />
[[4r0u]], [[4r0w]], [[4rik]], [[4ril]] - hSyn amyloid-forming peptide<br />
[[4znn]] - hSyn amyloid-forming peptide (mutant)<br />


== References ==
== References ==
<references/>
<references/>
 
</StructureSection>
[[Category:Topic Page]]
[[Category:Topic Page]]

Latest revision as of 12:02, 24 September 2024


Function

Alpha-Synuclein (Syn) is a human neuronal protein which has several roles in synaptic activity. Syn enhances vesicle priming, fusion and dilation of exocytotic pores[1]. Syn acts as a molecular chaperone in assisting the folding of SNAREs - the synaptic fusion components[2]. Syn associates with the dopamine transporter and modulates its activity[3].

Disease

Syn is a central component in the pathogenicity of Parkinson Disease (PD). PD is associated with deposition of Syn in the form of Lewy bodies throughout the brain and loss of dopaminergic neuronal cells[4].

Relevance

Various therapeutic approaches are investigated such as blocking of Syn receptors and searching for small molecules to target Syn aggregation and increase its degradation by increasing [5].

Structural highlights

The Syn structure shows forming segments interrupted by . Seven PD-associated familial are known. The 3D structure shows a which can provide an entry point for an incoming Syn molecule elongating the fibril[6].

3D Structures of alpha-synuclein

Alpha-synuclein 3D structures

References

  1. ↑ Logan T, Bendor J, Toupin C, Thorn K, Edwards RH. alpha-Synuclein promotes dilation of the exocytotic fusion pore. Nat Neurosci. 2017 May;20(5):681-689. doi: 10.1038/nn.4529. Epub 2017 Mar 13. PMID:28288128 doi:http://dx.doi.org/10.1038/nn.4529
  2. ↑ Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010 Sep 24;329(5999):1663-7. doi: 10.1126/science.1195227. Epub 2010, Aug 26. PMID:20798282 doi:http://dx.doi.org/10.1126/science.1195227
  3. ↑ Butler B, Saha K, Rana T, Becker JP, Sambo D, Davari P, Goodwin JS, Khoshbouei H. Dopamine Transporter Activity Is Modulated by alpha-Synuclein. J Biol Chem. 2015 Dec 4;290(49):29542-54. doi: 10.1074/jbc.M115.691592. Epub 2015, Oct 6. PMID:26442590 doi:http://dx.doi.org/10.1074/jbc.M115.691592
  4. ↑ Xu L, Pu J. Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application. Parkinsons Dis. 2016;2016:1720621. doi: 10.1155/2016/1720621. Epub 2016 Aug 17. PMID:27610264 doi:http://dx.doi.org/10.1155/2016/1720621
  5. ↑ Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Front Mol Neurosci. 2019 Dec 5;12:299. doi: 10.3389/fnmol.2019.00299. eCollection, 2019. PMID:31866823 doi:http://dx.doi.org/10.3389/fnmol.2019.00299
  6. ↑ Guerrero-Ferreira R, Taylor NMI, Mona D, Ringler P, Lauer ME, Riek R, Britschgi M, Stahlberg H. Cryo-EM structure of alpha-synuclein fibrils. Elife. 2018 Jul 3;7. pii: 36402. doi: 10.7554/eLife.36402. PMID:29969391 doi:http://dx.doi.org/10.7554/eLife.36402

Human alpha-synuclein (PDB 6h6b)

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Joel L. Sussman, Alexander Berchansky
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=Alpha-synuclein&oldid=4180222"